$APRE
Aprea Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003886 Filed on March 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $380.6K $14.08K $583.2K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.930M $1.643M $8.428M
YoY Change -42.67% -22.49% -59.81%
% of Gross Profit
Research & Development $1.600M $2.046M $7.627M
YoY Change 27.36% 284.96% -53.5%
% of Gross Profit
Depreciation & Amortization $6.157K $7.050K $7.050K
YoY Change 1401.71% -394.98% 60.12%
% of Gross Profit
Operating Expenses $3.530M $3.689M $16.06M
YoY Change -23.63% 39.12% -85.84%
Operating Profit -$3.150M -$15.47M
YoY Change -31.86% -86.36%
Interest Expense $283.4K $231.7K $1.185M
YoY Change 10.53% 10.59% 164.16%
% of Operating Profit
Other Income/Expense, Net $339.6K $1.185M
YoY Change 39.97% 62.31%
Pretax Income -$2.810M -$3.443M -$14.29M
YoY Change -35.84% 40.99% -87.32%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.810M -$3.443M -$14.29M
YoY Change -35.84% 40.99% -87.32%
Net Earnings / Revenue -738.39% -24454.9% -2449.59%
Basic Earnings Per Share -$0.67 -$3.95
Diluted Earnings Per Share -$0.67 -$0.92 -$3.95
COMMON SHARES
Basic Shares Outstanding 5.430M 3.737M 3.618M
Diluted Shares Outstanding 4.198M 3.618M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.37M $21.61M $21.61M
YoY Change 4.43% -24.94% -24.94%
Cash & Equivalents $32.40M $21.61M $21.61M
Short-Term Investments
Other Short-Term Assets $698.9K $914.3K $914.3K
YoY Change -31.67% -33.11% -33.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $33.07M $22.52M $22.52M
YoY Change 3.28% -25.31% -25.31%
LONG-TERM ASSETS
Property, Plant & Equipment $90.18K $88.36K $88.36K
YoY Change 4616.68% 3706.98% 3708.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.99K $40.72K $40.72K
YoY Change
Total Long-Term Assets $131.2K $129.1K $129.1K
YoY Change 6760.3% 5460.97% 5463.36%
TOTAL ASSETS
Total Short-Term Assets $33.07M $22.52M $22.52M
Total Long-Term Assets $131.2K $129.1K $129.1K
Total Assets $33.20M $22.65M $22.65M
YoY Change 3.68% -24.89% -24.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.318M $1.670M $1.670M
YoY Change 59.61% 98.2% 98.2%
Accrued Expenses $1.498M $2.186M $2.186M
YoY Change -55.95% -7.3% -7.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.965M $4.386M $4.386M
YoY Change -29.86% 37.0% 37.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.965M $4.386M $4.386M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.965M $4.386M $4.386M
YoY Change -29.86% 37.0% 37.0%
SHAREHOLDERS EQUITY
Retained Earnings -$310.9M -$308.1M
YoY Change 4.26% 4.86%
Common Stock $5.430K $3.736K
YoY Change 45.54% 40.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.92M $18.26M $18.26M
YoY Change
Total Liabilities & Shareholders Equity $33.20M $22.65M $22.65M
YoY Change 3.68% -24.89% -24.89%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.810M -$3.443M -$14.29M
YoY Change -35.84% 40.99% -87.32%
Depreciation, Depletion And Amortization $6.157K $7.050K $7.050K
YoY Change 1401.71% -394.98% 60.12%
Cash From Operating Activities -$3.936M -$3.738M -$12.18M
YoY Change 32.12% -7.04% -51.31%
INVESTING ACTIVITIES
Capital Expenditures $7.978K $3.090K $93.09K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.978K -$3.090K -$93.09K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.789M
YoY Change 747.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.71M -10.00 5.140M
YoY Change 186.18% -100.01% 652.59%
NET CHANGE
Cash From Operating Activities -3.936M -3.738M -12.18M
Cash From Investing Activities -7.978K -3.090K -93.09K
Cash From Financing Activities 14.71M -10.00 5.140M
Net Change In Cash 10.77M -3.741M -7.131M
YoY Change 398.21% -4.62% -70.69%
FREE CASH FLOW
Cash From Operating Activities -$3.936M -$3.738M -$12.18M
Capital Expenditures $7.978K $3.090K $93.09K
Free Cash Flow -$3.944M -$3.741M -$12.27M
YoY Change -6.96% -50.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001781983
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3736673
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2655269
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
528974
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4385605
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3201086
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39069
CY2023 dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
463-9385
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
APRE
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
10000000.0
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5430215
CY2023 dei Auditor Firm
AuditorFirmId
274
CY2023 dei Auditor Name
AuditorName
EisnerAmper LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21606820
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28786647
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
914275
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1366859
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22521095
CY2022Q4 us-gaap Assets Current
AssetsCurrent
30153506
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88362
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2321
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
40717
CY2023Q4 us-gaap Assets
Assets
22650174
CY2022Q4 us-gaap Assets
Assets
30155827
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1670369
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
842754
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3736673
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2655269
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3736
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2655
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335644204
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330060836
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10611273
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10623408
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308083161
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293796405
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22650174
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30155827
CY2023 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
583231
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7627491
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16402273
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
23895875
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8427703
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20969771
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13550478
CY2022 apre Acquired Research And Development In Process
AcquiredResearchAndDevelopmentInProcess
76020184
CY2023 us-gaap Operating Expenses
OperatingExpenses
16055194
CY2022 us-gaap Operating Expenses
OperatingExpenses
113392228
CY2021 us-gaap Operating Expenses
OperatingExpenses
37446353
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-15471963
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-113392228
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-37446353
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1224133
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
448667
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1648
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-38926
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
281534
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
317402
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1185207
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
730201
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
319050
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14286756
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-112662027
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12135
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-264452
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-321695
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14274621
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-112926479
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37448998
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.95
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.95
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-67.99
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-67.99
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.88
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3617607
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3617607
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1657055
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1657055
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1064325
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1064325
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
77395207
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208367
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1538645
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7813743
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-321695
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1329699
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2602850
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
682973
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
67466405
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16981266
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-264452
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-112662027
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
444459
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12135
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14286756
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2023 us-gaap Profit Loss
ProfitLoss
-14286756
CY2022 us-gaap Profit Loss
ProfitLoss
-112662027
CY2021 us-gaap Profit Loss
ProfitLoss
-37127303
CY2022 apre Research And Development In Process Noncash
ResearchAndDevelopmentInProcessNoncash
72523293
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7052
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4403
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12829
CY2023 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
444459
CY2022 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
16981266
CY2021 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7813743
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
182042
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
258848
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-38926
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
281534
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
317402
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-451994
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2190086
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109338
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
827463
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-858513
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2730587
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-189720
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2903450
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5218241
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
528974
CY2022 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-186702
CY2021 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-268728
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12177608
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25011136
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37686179
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
93093
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-93093
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208367
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
682973
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1538645
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
682973
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1747012
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7130711
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-24328163
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-35939167
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8399
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38758
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2467
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89017686
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21647537
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21606820
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28786647
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53076052
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
40717
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21647537
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
123786
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
124043
CY2022 us-gaap Stock Issued1
StockIssued1
70107167
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk</b>—Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p>
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
41000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
648448
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
521120
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
249293
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
138484
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
45391
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50122
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43070
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88362
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2321
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7052
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4403
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12829
CY2023Q4 apre Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
1
CY2023 apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
110000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41784757
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38839281
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3955371
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2309828
CY2023Q4 apre Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
56882
CY2022Q4 apre Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
118259
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
233628
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
233364
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
245584
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
255078
CY2022 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
123786
CY2021 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
124043
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138601
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75012
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016960
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1397977
CY2023Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
856575
CY2022Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
688858
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174126
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196485
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14286756
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-112662027
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.006
CY2023 apre Effective Income Tax Rate Reconciliation Section162 Limitation Percent
EffectiveIncomeTaxRateReconciliationSection162LimitationPercent
0.103
CY2022 apre Effective Income Tax Rate Reconciliation Section162 Limitation Percent
EffectiveIncomeTaxRateReconciliationSection162LimitationPercent
-0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.135
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.311
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.037
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.182
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.027
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3487955
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2362347
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3574
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
155320
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49443859
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43629715
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49443859
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43629689
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
26
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
26
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
26
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5800000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1500000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023 apre Research And Development Capitalized
ResearchAndDevelopmentCapitalized
7800000
CY2022 apre Research And Development Capitalized
ResearchAndDevelopmentCapitalized
9000000.0
CY2023Q4 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023 apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2020Q4 apre Universal Shelf Registration Maximum Amount To Be Issued
UniversalShelfRegistrationMaximumAmountToBeIssued
350000000.0
CY2023 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-24-003886-index-headers.html Edgar Link pending
0001558370-24-003886-index.html Edgar Link pending
0001558370-24-003886.txt Edgar Link pending
0001558370-24-003886-xbrl.zip Edgar Link pending
apre-20231231.xsd Edgar Link pending
apre-20231231x10k.htm Edgar Link pending
apre-20231231x10k001.jpg Edgar Link pending
apre-20231231x10k002.jpg Edgar Link pending
apre-20231231x10k003.jpg Edgar Link pending
apre-20231231x10k004.jpg Edgar Link pending
apre-20231231x10k005.jpg Edgar Link pending
apre-20231231x10k006.jpg Edgar Link pending
apre-20231231x10k007.jpg Edgar Link pending
apre-20231231x10k008.jpg Edgar Link pending
apre-20231231x10k009.jpg Edgar Link pending
apre-20231231x10k010.jpg Edgar Link pending
apre-20231231x10k011.jpg Edgar Link pending
apre-20231231x10k012.jpg Edgar Link pending
apre-20231231x10k013.jpg Edgar Link pending
apre-20231231xex19.htm Edgar Link pending
apre-20231231xex21d1.htm Edgar Link pending
apre-20231231xex23d1.htm Edgar Link pending
apre-20231231xex23d2.htm Edgar Link pending
apre-20231231xex31d1.htm Edgar Link pending
apre-20231231xex31d2.htm Edgar Link pending
apre-20231231xex32d1.htm Edgar Link pending
apre-20231231xex32d2.htm Edgar Link pending
apre-20231231xex4d1.htm Edgar Link pending
apre-20231231xex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
apre-20231231_pre.xml Edgar Link unprocessable
apre-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20231231x10k_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apre-20231231_def.xml Edgar Link unprocessable
apre-20231231_cal.xml Edgar Link unprocessable